Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

sevelamer

- PMLiVE

Smart watch epilepsy monitor cleared by FDA

Approval could potentially clear the way for insurers to reimburse its cost

- PMLiVE

EMA set to review Teva’s migraine injection

Fremanezumab could be approved for prophylactic use of migraines

Sanofi reception

Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi

The offer comes at a 110% premium on the Belgian biopharma’s share price

- PMLiVE

Dominique Carouge joins Sanofi as head of business transformation

He also becomes a member of the executive committee

Sanofi reception

Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

French pharma firm offers $105 apiece for the spin-out’s shares

AstraZeneca AZ

AZ gets EMA green light for severe asthma drug Fasenra

The biologic respiratory treatment will go up against GSK’s Nucala and Teva’s Cinqaero

Sanofi reception

Sanofi and Regeneron ramp up immuno-oncology collaboration

Will put an additional $1bn in investigational candidate cemiplimab

Sanofi reception

FDA lifts clinical hold on Sanofi’s haemophilia drug

Phase II and III trials of fitusiran can now resume

- PMLiVE

Teva cuts 25% of workforce, with Israel taking a heavy toll

But share prices increase by almost 14%

Sanofi reception

Sanofi/Regeneron start first filings for PD-1 drug cemiplimab

The pharma partners begin with a skin cancer filing to the US FDA

Sanofi reception

Sanofi/Regeneron start first filings for PD-1 drug cemiplimab

The pharma partners begin with a skin cancer filing to the US FDA

Sanofi reception

After some big setbacks, Sanofi talks up its R&D portfolio

Hopes its pipeline of 71 projects delivers strong sales

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links